» Articles » PMID: 10373516

C-Myc Regulates Cyclin D-Cdk4 and -Cdk6 Activity but Affects Cell Cycle Progression at Multiple Independent Points

Overview
Journal Mol Cell Biol
Specialty Cell Biology
Date 1999 Jun 22
PMID 10373516
Citations 144
Authors
Affiliations
Soon will be listed here.
Abstract

c-myc is a cellular proto-oncogene associated with a variety of human cancers and is strongly implicated in the control of cellular proliferation, programmed cell death, and differentiation. We have previously reported the first isolation of a c-myc-null cell line. Loss of c-Myc causes a profound growth defect manifested by the lengthening of both the G1 and G2 phases of the cell cycle. To gain a clearer understanding of the role of c-Myc in cellular proliferation, we have performed a comprehensive analysis of the components that regulate cell cycle progression. The largest defect observed in c-myc-/- cells is a 12-fold reduction in the activity of cyclin D1-Cdk4 and -Cdk6 complexes during the G0-to-S transition. Downstream events, such as activation of cyclin E-Cdk2 and cyclin A-Cdk2 complexes, are delayed and reduced in magnitude. However, it is clear that c-Myc affects the cell cycle at multiple independent points, because restoration of the Cdk4 and -6 defect does not significantly increase growth rate. In exponentially cycling cells the absence of c-Myc reduces coordinately the activities of all cyclin-cyclin-dependent kinase complexes. An analysis of cyclin-dependent kinase complex regulators revealed increased expression of p27(KIP1) and decreased expression of Cdk7 in c-myc-/- cells. We propose that c-Myc functions as a crucial link in the coordinate adjustment of growth rate to environmental conditions.

Citing Articles

Effects of lysine and methionine on mRNA expression of candidate transcription factors by primary bovine mammary epithelial cells.

Li B, Edick A, Fox M, Doelman J, Burgos S, Cant J PLoS One. 2024; 19(12):e0305440.

PMID: 39705261 PMC: 11661575. DOI: 10.1371/journal.pone.0305440.


MicroRNA signatures in osteosarcoma: diagnostic insights and therapeutic prospects.

Dey M, Skipar P, Bartnik E, Piatkowski J, Sulejczak D, Czarnecka A Mol Cell Biochem. 2024; .

PMID: 39419925 DOI: 10.1007/s11010-024-05135-5.


Unveiling Conformational States of CDK6 Caused by Binding of Vcyclin Protein and Inhibitor by Combining Gaussian Accelerated Molecular Dynamics and Deep Learning.

Zhao L, Wang J, Yang W, Zhao K, Sun Q, Chen J Molecules. 2024; 29(11).

PMID: 38893554 PMC: 11174096. DOI: 10.3390/molecules29112681.


Low levels of sex hormone-binding globulin predict an increased breast cancer risk and its underlying molecular mechanisms.

Zhao S, Gu J, Tian Y, Wang R, Li W Open Life Sci. 2024; 19(1):20220822.

PMID: 38465341 PMC: 10921478. DOI: 10.1515/biol-2022-0822.


A dynamic Boolean network reveals that the BMI1 and MALAT1 axis is associated with drug resistance by limiting miR-145-5p in non-small cell lung cancer.

Gupta S, Silveira D, Piedade G, Ostrowski M, Mombach J, Hashimoto R Noncoding RNA Res. 2023; 9(1):185-193.

PMID: 38125755 PMC: 10730431. DOI: 10.1016/j.ncrna.2023.10.008.


References
1.
Diehl J, Cheng M, Roussel M, Sherr C . Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998; 12(22):3499-511. PMC: 317244. DOI: 10.1101/gad.12.22.3499. View

2.
Bush A, Mateyak M, Dugan K, Obaya A, Adachi S, Sedivy J . c-myc null cells misregulate cad and gadd45 but not other proposed c-Myc targets. Genes Dev. 1998; 12(24):3797-802. PMC: 317273. DOI: 10.1101/gad.12.24.3797. View

3.
Iyer V, Eisen M, Ross D, Schuler G, Moore T, Lee J . The transcriptional program in the response of human fibroblasts to serum. Science. 1999; 283(5398):83-7. DOI: 10.1126/science.283.5398.83. View

4.
Cole M, McMahon S . The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation. Oncogene. 1999; 18(19):2916-24. DOI: 10.1038/sj.onc.1202748. View

5.
Obaya A, Mateyak M, Sedivy J . Mysterious liaisons: the relationship between c-Myc and the cell cycle. Oncogene. 1999; 18(19):2934-41. DOI: 10.1038/sj.onc.1202749. View